Q-omics provides the consensus-scored NANOGP4 profile across patient tissues and cancer cell-line models. NANOGP4 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, NANOGP4 is differentially expressed in 6, with the highest sampling consensus in KICH. Additionally, NANOGP4 RNA expression shows 11,679 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KICH, and TGCT as cancer lineages where NANOGP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NANOGP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NANOGP4 survival associations across molecular data types. NANOGP4 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NANOGP4 RNA expression–survival associations across cancer types. High NANOGP4 expression shows unfavorable associations in UVM, LUSC, UCEC and ACC, but favorable associations in BRCA and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for NANOGP4 RNA expression.
This table summarizes NANOGP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for NANOGP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NANOGP4 shows lower tumor expression in KICH, THCA and LUAD and higher tumor expression in STAD, COAD and HNSC. The KICH box plot shows higher NANOGP4 RNA expression in normal versus tumor tissue (log2 FC = −0.078, t-test p = .004).
This table shows molecular features associated with NANOGP4 in patient tissues and cancer cell lines. In patient samples, NANOGP4 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
